Does Testosterone Therapy Make Gout Worse?

Testosterone therapy raises uric acid levels, and for people with gout or borderline-high uric acid, that increase can trigger flares or make the disease harder to manage. Studies of people receiving testosterone have documented uric acid climbing within as little as three months, with a dose-dependent pattern. The relationship involves at least two biological pathways, and the practical risk depends on factors like your baseline uric acid, kidney function, and how much testosterone you’re receiving.

How Testosterone Pushes Uric Acid Up

Two mechanisms work in parallel to explain why testosterone raises uric acid. The first involves the kidneys. Most uric acid exits the body through the kidneys, where specific transporter proteins determine how much gets reabsorbed back into the bloodstream versus flushed out in urine. In animal studies, testosterone boosted levels of a kidney transporter called SMCT1 that pulls uric acid back into the blood, meaning the kidneys under testosterone’s influence hold onto more uric acid rather than excreting it.¹

The second mechanism is more straightforward: testosterone promotes muscle growth, and muscle tissue is a significant source of purines, the compounds the body breaks down into uric acid. Researchers have documented a positive correlation between rising creatinine (a marker of muscle mass) and rising uric acid during testosterone therapy. The authors of one study concluded that the uric acid elevation seen during treatment is “at least partially attributed to an increase in muscle mass.”²

So the body is both producing more uric acid (from additional muscle) and eliminating less of it (because the kidneys are reabsorbing more). That double hit can shift someone from normal uric acid levels into the range where urate crystals begin to form.

What the Clinical Evidence Shows

Some of the clearest data comes from studies of transgender men receiving testosterone for gender-affirming hormone therapy. These individuals start with female-range uric acid levels and then receive substantial testosterone doses, creating a clean before-and-after comparison that would be difficult to study in cisgender men already producing testosterone.

One study found that serum uric acid rose significantly after just three months of testosterone replacement, with a tendency toward dose-dependency: people on higher doses were more likely to develop hyperuricemia.³ A meta-analysis pooling results from multiple studies on testosterone therapy in the same population confirmed these findings broadly, reporting significant increases in both creatinine and uric acid at all follow-up time points.⁴

Perhaps the most vivid illustration is a published case report of a 48-year-old transgender man who developed recurrent gout attacks after starting testosterone therapy and undergoing oophorectomy for gender reassignment. This patient had no prior history of gout. After fifteen years on testosterone, gout appeared at age 46, with crystal deposits confirmed in the joints.⁵ The case showed that hormone-driven hyperuricemia is fully capable of producing clinical gout in someone who previously had none.

The underlying biology here, kidney transporter changes and increased muscle mass, applies to cisgender men receiving TRT as well. The transgender cohorts simply provide cleaner study conditions because the hormonal shift is larger and the pre-treatment baseline is well documented.

The Paradox of Low Testosterone and High Uric Acid

Here’s where things get counterintuitive. Large population studies have found that men who already have low testosterone tend to have higher uric acid levels, not lower. A cross-sectional analysis of thousands of U.S. men found that each additional mg/dL of uric acid was associated with about a 4.4% decline in testosterone. Men with low testosterone were also more likely to be obese, insulin resistant, and to have elevated uric acid.⁶

This seems to contradict the idea that testosterone raises uric acid. But the explanation lies in the broader metabolic picture. Low testosterone in men is closely tied to obesity and metabolic syndrome, both of which independently drive uric acid levels up through increased purine production, insulin resistance (which impairs the kidneys’ ability to excrete uric acid), and other pathways. The low-testosterone, high-uric-acid pattern reflects metabolic dysfunction rather than a direct effect of testosterone deficiency itself.

This matters practically because it means the men most likely to be prescribed TRT, those with symptomatic low testosterone, often already have elevated uric acid before treatment starts. Adding exogenous testosterone on top of already-high levels could push them past the saturation point where urate crystals form in joints, typically around 6.8 mg/dL.

Does Dose Make the Difference?

The evidence points toward a dose-dependent relationship. In the study of transgender men, those receiving higher testosterone doses were more likely to develop hyperuricemia than those on lower doses.³ This tracks with the biology: more testosterone means more transporter upregulation in the kidneys and more muscle growth, amplifying both pathways.

For cisgender men on standard TRT doses prescribed for hypogonadism, the uric acid bump is likely smaller than what’s seen in transgender men receiving gender-affirming doses, which aim for full male-range testosterone starting from a female baseline. But even modest increases in uric acid can matter if you’re already hovering near the crystallization threshold. Someone sitting at 6.5 mg/dL who sees a bump to 7.2 mg/dL may not notice anything in their bloodwork until a toe joint swells at 3 a.m.

Different delivery methods, injections versus gels versus pellets, create different testosterone peaks and troughs, but no study has directly compared how delivery route affects uric acid. What matters most is the sustained testosterone level achieved over time rather than how the hormone gets into your body.

If You Already Have Gout

For someone with established gout, starting TRT creates a specific set of practical concerns. Gout flares are triggered by shifts in uric acid levels, including rapid increases. Beginning testosterone therapy introduces new upward pressure on uric acid that can destabilize a situation that previously seemed well controlled.

If you’re already taking a urate-lowering medication like allopurinol or febuxostat, your dose may need adjustment after starting TRT. The target serum uric acid for gout management is generally below 6 mg/dL, and testosterone’s uric-acid-raising effect could push you above that threshold even on a medication regimen that previously kept you in range. If you have a history of gout but aren’t currently on urate-lowering therapy, starting TRT without monitoring your uric acid is risky. The case report described earlier illustrates that hormone-driven hyperuricemia can produce the same crystal deposits and painful flares as any other cause of elevated uric acid.⁵

A few practical steps worth discussing with your doctor before and during TRT:

Baseline testing: Get a serum uric acid level drawn before starting testosterone so you know your starting point.
Early recheck: Retest uric acid within three months of starting therapy, since that is when elevations have been documented to appear.³
Dose review: If uric acid rises significantly, consider whether the TRT dose can be lowered or whether urate-lowering medication should be started or increased.
Hydration: Adequate fluid intake supports the kidneys in excreting uric acid and is one of the simplest protective measures.
Dietary awareness: High-purine foods (organ meats, certain shellfish, some fish) and alcohol interact with the testosterone-driven increase. You don’t necessarily need to eliminate these entirely, but being mindful of them becomes more important when another variable is pushing uric acid upward.

Why Gout Risk Gets Overlooked in TRT Discussions

Uric acid isn’t part of the standard blood panel that most TRT-prescribing clinicians monitor. The typical surveillance protocol focuses on testosterone levels, estradiol, hematocrit (because testosterone stimulates red blood cell production), PSA, and liver function. Uric acid falls outside that checklist, so it often goes untested unless you specifically have a known gout history or raise the issue yourself.

This gap means that you could develop hyperuricemia on TRT and not know it until a flare strikes. Given that gout is already the most common form of inflammatory arthritis in men, and that TRT is increasingly prescribed to aging men in a higher-risk demographic, the oversight feels meaningful. The meta-analysis that found consistent uric acid elevations at every follow-up point strengthens the argument for adding it to routine monitoring.⁴ Whether that will translate into updated clinical guidelines for TRT monitoring is an open question.

Estrogen’s Protective Role and What It Reveals

Part of the reason testosterone’s effect on uric acid shows up so dramatically in transgender men is that testosterone therapy is often paired with the loss of estrogen, either through oophorectomy or hormonal suppression. Estrogen has a well-established protective effect against hyperuricemia: it promotes uric acid excretion through the kidneys, which is a major reason premenopausal women have substantially lower uric acid levels and gout rates than men of the same age. After menopause, when estrogen drops, women’s uric acid levels rise and their gout rates begin converging with men’s.

In the case report of the transgender man who developed gout, the patient had undergone bilateral oophorectomy in addition to receiving testosterone.⁵ That combination removed estrogen’s protective effect while simultaneously adding testosterone’s uric-acid-raising effect, creating an especially sharp shift in urate balance.

For cisgender men starting TRT, estrogen isn’t being removed. But the principle still matters in a subtler way. Some TRT protocols include aromatase inhibitors to prevent testosterone from converting to estrogen, and if estrogen is suppressed too aggressively, the kidney’s ability to excrete uric acid may be reduced. This is another pathway through which TRT management decisions can inadvertently raise gout risk, one that rarely comes up in the standard conversation between patient and prescriber.

Could TRT Ever Help the Metabolic Picture?

The relationship between testosterone, metabolism, and uric acid isn’t entirely one-directional in theory. Restoring testosterone to normal levels in men with genuine hypogonadism can improve insulin sensitivity, reduce visceral fat, and shift several metabolic markers in a favorable direction. Since insulin resistance itself impairs the kidneys’ ability to clear uric acid, there’s a theoretical scenario where correcting severe testosterone deficiency might improve the metabolic environment enough to partly offset the direct uric-acid-raising effects of the hormone.

In practice, no clinical study has demonstrated this offsetting effect. The available evidence consistently shows uric acid going up with testosterone therapy, not down.⁴ The metabolic improvements from TRT are real, but they don’t appear large enough to counterbalance the kidney transporter changes and increased purine production from muscle growth. A man with severe metabolic syndrome and very low testosterone is in a different clinical situation than a man with borderline-low testosterone and an otherwise healthy metabolic profile, and the net effect on uric acid likely varies between them. But the direction of the direct hormonal effect is reliably upward, and for practical purposes, that’s the variable to plan around.